New research published in Current Pharmaceutical Analysis delves into the activity of the tumor necrosis factor-alpha (TNF-α) system in patients with central nervous system disorders such as ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (TNFA) (“TNF” or the “Company”), a ...
“We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for Translational Medicine. “And TNF-α is still the most contested—and the most ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto’s thyroiditis BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, ...
GMP Human TNF-alpha Protein (Cat. No. GMP-TNAH23) is expressed in human 293 cells (HEK293) and comprises amino acids Val 77 to Leu 233 (Accession # P01375). This protein has no "tag". It has a ...
Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...
In the study, published in Oncogene, a world-leading international team of scientists and clinicians explore the potential of necrosis – when cells die unexpectedly as a result of infection, injury or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results